MedicaidPrior AuthMedium impact
KMAP BULLETIN: Preferred Drug List Update
Kansas Medicaid (KanCare)·KS · Rheumatology, Gastroenterology, Dermatology +3 more·Pharmacy
Effective date
Mar 1, 2024
We identified it
Jun 21, 2026
Summary
Kansas Medicaid has updated their Preferred Drug List effective March 1, 2024, requiring prior authorization for several adalimumab biosimilars and other specialty medications including Bimzelx, Cabtreo, Vevye, Velsipity, Lyfgenia, Rasuvo, Omvoh, Suflave, and Cosentyx vial. Several medications have been moved to preferred status, potentially reducing prior auth requirements.
Action Required
By March 1, 2024: Billing team must update prior authorization workflows to require PA for newly listed adalimumab biosimilars (Abrilada, Amjevita, Cyltezo, Hulio, Hyrimoz, Idacio, Yuflyma) and specialty medications (Bimzelx, Cabtreo, Vevye, Velsipity, Lyfgenia, Rasuvo, Omvoh, Suflave, Cosentyx vial) for Kansas Medicaid patients. Update EMR alerts and provider notification systems. Monitor KanCare MCO implementation dates as they may vary from the state effective date.